Nov 5, 4:08 PM ET
Halozyme Therapeutics reported third quarter 2026 total revenue of $493 million, representing a 39% increase year-over-year, alongside net income of $247 million. Driven by strong partner product sales and royalty growth, the company raised its full-year 2026 financial guidance ranges for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS.
- Total revenue increased 39% year-over-year to $493 million for the third quarter ended September 30, 2026.
- Royalty revenue grew 44% year-over-year to $341 million.
- Full-year 2026 total revenue guidance was raised to a range of $1.860 billion to $1.925 billion.
- The Dutch patent court issued an injunction against Merck prohibiting the launch of Keytruda Qlex in multiple European markets.
Read the filing on SEC.gov ↗
Sep 30, 4:20 PM ET
Halozyme Therapeutics elected James Daly to its Board of Directors on September 28, 2026, disclosed in a filing dated September 30, 2026. Mr. Daly was placed in the class of directors with terms ending at the 2029 annual meeting and was not initially assigned to any Board committee.
- Board election date: September 28, 2026
- Term ends at the company's annual meeting of stockholders in 2029
- Not initially assigned to any Board committee
- Compensated under the non-employee director program; no related person transactions or election arrangements disclosed
Read the filing on SEC.gov ↗
Sep 22, 4:41 PM ET
Halozyme Therapeutics completed the sale of $1,500.0 million of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, including $200.0 million from the initial purchasers' option. The company received net proceeds of approximately $1,471.1 million and plans to use part of them to repurchase existing 2027 and 2028 convertible notes, which adds new debt while potentially reducing older debt.
- $1,500.0 million aggregate principal of 1.50% Convertible Senior Notes due 2033 sold, including a $200.0 million option exercise
- Net proceeds of approximately $1,471.1 million, with $187.5 million used to fund capped call transactions
- Expected repurchases of about $217.0 million of 2027 Notes and about $435.5 million of 2028 Notes, including accrued interest
- Initial conversion price of approximately $139.84 per share; interest paid semi-annually starting April 1, 2027
Read the filing on SEC.gov ↗
Aug 18, 4:04 PM ET
Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026, in the class with terms ending at the 2028 annual meeting. She was not initially assigned to any Board committee, and the filing says she will receive compensation under the standard non-employee director program.
- Board election effective August 14, 2026; term ends at the 2028 annual meeting of stockholders
- Not initially assigned to any Board committee
- Compensation follows the non-employee director program (cash retainers, restricted stock and stock options)
- Filing states no arrangements or related person transactions with the company
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.